Stay updated on Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial

Sign up to get notified when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:28:07.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating an update in the number of participant cohorts being evaluated for the efficacy and safety of poziotinib in non-small cell lung cancer (NSCLC) with EGFR or HER2 exon 20 insertion mutation. This change reflects the addition of three new cohorts (Cohorts 5, 6, and 7) to the study.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:42.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as willingness to provide informed consent and adherence to study protocols, as well as specific health conditions and prior treatments. Previously, this section had no information provided.
    Difference
    19%
    Check dated 2024-05-22T21:29:55.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:27:55.000Z thumbnail image

Stay in the know with updates to Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.